Principal Scientist, DMPK at Cytokinetics

South San Francisco, California, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biopharmaceutical, CardiovascularIndustries

Requirements

PhD in Pharmacology, Pharmaceutical Sciences, Chemistry, or related field
8+ years of relevant experience in bioanalytical sciences and pharmacokinetics within the pharmaceutical/biotech industry
Deep expertise in LC-MS/MS, Orbitrap, Q-TOF and HPLC methods
Strong background in PK modeling (WinNonlin, Phoenix, NONMEM, R, etc.) and interpretation of PK/PD data
Experience with regulatory submissions (FDA/EMA/ICH guidelines) and working in a GLP/GCP environment
Proven leadership skills with the ability to influence cross-functional teams and mentor junior scientists
Excellent communication, problem-solving, and project management abilities
Familiarity with DMPK principles (metabolism, transporters, drug-drug interactions)
Knowledge of automation and high-throughput bioanalytical techniques

Responsibilities

Lead the design, execution, and interpretation of bioanalytical (BA) and pharmacokinetic (PK) studies to support preclinical and clinical development
Hands-on and oversee method development, validation, and sample analysis for small molecules, and/or novel modalities (e.g., siRNA, PROTAC) using Sciex LC-MS/MS, Orbitrap, or Q-TOF machines
Perform non-compartmental (NCA) and compartmental PK analysis, PK/PD modeling, and translational pharmacokinetics to guide compound optimization and dosing strategies
Author and review technical reports, regulatory submissions (INDs, NDAs, BLAs), and scientific publications
Collaborate closely with toxicology, clinical pharmacology, CMC, and discovery teams to ensure suitable study design and robust PK/PD understanding of drug candidates
Leverage specialized ADME/PK skills such as in vitro ADME, in vivo ADME, biotransformation, PK/PD, or physiologically-based pharmacokinetic modeling (PBPK) to impact project progression and decision-making
Manage external CROs for bioanalytical and PK studies, ensuring data quality and regulatory compliance (GLP/GCP)
Mentor junior scientists and contribute to departmental initiatives to enhance scientific and operational excellence
Independently troubleshoot and resolve Sciex LC-MS/MS challenges as they arise in the lab

Skills

LC-MS/MS

Orbitrap

Q-TOF

PK/PD modeling

PBPK

ADME

NCA

GLP

GCP

bioanalytical

pharmacokinetics

siRNA

PROTAC

Cytokinetics

Develops drugs for muscle function disorders

About Cytokinetics

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, tailored to specific therapeutic needs. The company has a pipeline of drugs, including omecamtiv mecarbil and reldesemtiv, which are in various stages of clinical trials. Unlike many competitors, Cytokinetics emphasizes rigorous scientific research and has conducted over 50 clinical trials to ensure the effectiveness of its treatments. The goal is to bring new therapies to market that address the unmet needs of patients suffering from conditions like heart failure, ALS, and HCM.

South San Francisco, CaliforniaHeadquarters

1998Year Founded

$58.4MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

501-1,000Employees

Risks

Increased competition could impact market share and profitability.

Potential delays in clinical trials could hinder drug commercialization.

Dependence on strategic partnerships may expose Cytokinetics to risks if challenges arise.

Differentiation

Cytokinetics focuses on muscle activators and inhibitors for cardiovascular and neuromuscular diseases.

The company has a robust pipeline including omecamtiv mecarbil and aficamten.

Cytokinetics engages in strategic partnerships, like with Sanofi, to expand market reach.

Upsides

Recent investments indicate strong interest in muscle activators and inhibitors.

Strategic partnerships, like with Sanofi, expand market reach and potential revenue.

Significant funding from Royalty Pharma supports commercial launch and R&D advancements.

Land your dream remote job 3x faster with AI

Try Jobo Free